Akeso Inc
HKEX:9926

Watchlist Manager
Akeso Inc Logo
Akeso Inc
HKEX:9926
Watchlist
Price: 59.9 HKD -1.56% Market Closed
Market Cap: 53.8B HKD
Have any thoughts about
Akeso Inc?
Write Note

Akeso Inc
Current Portion of Long-Term Debt

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Akeso Inc
Current Portion of Long-Term Debt Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Current Portion of Long-Term Debt CAGR 3Y CAGR 5Y CAGR 10Y
Akeso Inc
HKEX:9926
Current Portion of Long-Term Debt
ÂĄ451.9m
CAGR 3-Years
200%
CAGR 5-Years
76%
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
Current Portion of Long-Term Debt
ÂĄ358.8m
CAGR 3-Years
57%
CAGR 5-Years
43%
CAGR 10-Years
N/A
Innovent Biologics Inc
HKEX:1801
Current Portion of Long-Term Debt
ÂĄ1B
CAGR 3-Years
38%
CAGR 5-Years
124%
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Current Portion of Long-Term Debt
ÂĄ13.3m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Current Portion of Long-Term Debt
ÂĄ61.3m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Imeik Technology Development Co Ltd
SZSE:300896
Current Portion of Long-Term Debt
ÂĄ15m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Akeso Inc
Glance View

Market Cap
51.9B HKD
Industry
Biotechnology

In the bustling landscape of biotechnology, Akeso Inc. emerges as a dynamic force addressing the dynamic and often daunting challenges of the medical world. Founded in 2012 and headquartered in China, this innovative company has made significant strides in the realm of biopharmaceuticals, particularly focusing on the research and development of novel therapies for oncology and immunology. Akeso Inc. differentiates itself through its comprehensive end-to-end approach, spanning discovery, clinical development, and commercialization. By leveraging its robust pipeline of therapeutic antibodies, the company constantly seeks to pioneer breakthroughs in cancer treatment and autoimmune disorders, thus driving its mission to enhance patient outcomes and address unmet medical needs. The economic engine of Akeso Inc. is driven by its ability to transform scientific research into viable therapeutic products. Revenue generation centers around the commercialization of their proprietary drugs, which often involves collaborations and strategic partnerships with major pharmaceutical players globally. These alliances not only expand the reach of Akeso's innovations but also provide essential capital and shared expertise that accelerate product advancement. The company's business model is further bolstered by licensing agreements and milestone payments, creating a steady stream of income as they navigate the rigorous pathways of drug approval and market entry. Through these ventures, Akeso Inc. not only secures its financial health but also continuously reinvests in its research endeavors, fueling a cycle of innovation that propels it forward in the competitive biotech arena.

Intrinsic Value
59.24 HKD
Overvaluation 1%
Intrinsic Value
Price

See Also

What is Akeso Inc's Current Portion of Long-Term Debt?
Current Portion of Long-Term Debt
451.9m CNY

Based on the financial report for Dec 31, 2023, Akeso Inc's Current Portion of Long-Term Debt amounts to 451.9m CNY.

What is Akeso Inc's Current Portion of Long-Term Debt growth rate?
Current Portion of Long-Term Debt CAGR 5Y
76%

Over the last year, the Current Portion of Long-Term Debt growth was 0%. The average annual Current Portion of Long-Term Debt growth rates for Akeso Inc have been 200% over the past three years , 76% over the past five years .

Back to Top